Regeneron Announces Investor Conference Presentations
06 Fevereiro 2024 - 6:05PM
Regeneron Pharmaceuticals, Inc. (NASDAQ:
REGN)
will webcast management participation as follows:
- Oppenheimer 34th Annual Healthcare Life Sciences Conference at
1:20 p.m. ET on Wednesday, February 14, 2024
- TD Cowen 44th Annual Health Care Conference at 11:10 a.m. ET on
Wednesday, March 6, 2024
- Barclays 26th Annual Global Healthcare Conference at 11:15 a.m.
ET on Tuesday, March 12, 2024
- Leerink Partners Global Biopharma Conference 2024 at 10:40 a.m.
ET on Wednesday, March 13, 2024
The sessions may be accessed from the "Investors
& Media" page of Regeneron's website at
https://investor.regeneron.com/events-and-presentations. Replays
and transcripts of the webcasts will be archived on the Company's
website for at least 30 days.
About Regeneron Regeneron is a
leading biotechnology company that invents, develops, and
commercializes life-transforming medicines for people with serious
diseases. Founded and led for over 35 years by
physician-scientists, Regeneron's unique ability to repeatedly and
consistently translate science into medicine has led to numerous
FDA-approved treatments and product candidates in development,
almost all of which were homegrown in Regeneron's laboratories.
Regeneron's medicines and pipeline are designed to help patients
with eye diseases, allergic and inflammatory diseases, cancer,
cardiovascular and metabolic diseases, hematologic conditions,
infectious diseases, and rare diseases.
Regeneron is accelerating and improving the
traditional drug development process through its
proprietary VelociSuite® technologies, such
as VelocImmune®, which uses unique genetically
humanized mice to produce optimized fully
human antibodies and bispecific antibodies, and through
ambitious research initiatives such as the Regeneron Genetics
Center®, which is conducting one of the largest genetics sequencing
efforts in the world.
For additional information about Regeneron, please
visit www.regeneron.com or follow Regeneron on
LinkedIn.
Contact Information: Investor
Relations Ryan Crowe 914.847.8790
ryan.crowe@regeneron.com
Regeneron Pharmaceuticals (NASDAQ:REGN)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024